NGEN
NervGen Pharma Corp.
NasdaqCMUSDEQUITY
DELAYED
Last price
1.89
▲ 0.13 (7.36%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
1.78
Prev close
1.76
Day high
1.86
Day low
1.73
Volume
531.03K
Market cap
—
P/E (TTM)
—
52W range
1.58 – 6.30
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
+7.20%
+8.6%
1M
+11.04%
+7.3%
3M
-49.46%
-52.6%
6M
-58.20%
-69.3%
YTD
-66.79%
-79.1%
1Y
-6.72%
-26.7%
3Y
+37.68%
-36.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $13.91M | $15.81M | $8.05M | $16.61M | -12.0% |
| Selling, general & admin | $11.17M | $9.34M | $9.63M | $6.34M | +19.7% |
| Total operating expense | $25.08M | $25.18M | $17.78M | $23.03M | -0.4% |
| Operating income | -$25.08M | -$25.18M | -$17.78M | -$23.03M | +0.4% |
| Net interest income | $333.42K | $812.62K | $550.07K | -$313.20K | -59.0% |
| Pre-tax income | -$44.12M | -$24.25M | -$22.38M | -$20.72M | -81.9% |
| Net income | -$44.12M | -$24.25M | -$22.38M | -$20.72M | -81.9% |
| Net income to common | -$44.12M | -$24.25M | -$22.38M | -$20.72M | -81.9% |
| Basic EPS | -0.61 | -0.36 | -0.38 | -0.39 | -69.4% |
| Diluted EPS | -0.61 | -0.36 | -0.38 | -0.39 | -69.4% |
| EBIT | -$25.08M | -$25.18M | -$17.78M | -$20.21M | +0.4% |
| EBITDA | -$25.02M | -$25.09M | -$17.63M | -$20.09M | +0.3% |
| Basic shares | 72.33M | 67.32M | 59.29M | 52.65M | +7.4% |
| Diluted shares | 72.33M | 67.32M | 59.29M | 52.65M | +7.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $22.07M | $17.27M | $11.66M | $22.45M | — | +27.8% |
| Cash & short-term investments | $22.08M | $17.36M | $11.66M | $22.45M | — | +27.1% |
| Accounts receivable | — | — | $250.21K | $27.03K | $64.00K | — |
| Total current assets | $22.80M | $19.01M | $12.52M | $23.15M | — | +19.9% |
| Property, plant & equipment | $0 | $0 | $199.78K | $295.28K | — | — |
| Goodwill & intangibles | $409.16K | $464.96K | $520.75K | $431.40K | — | -12.0% |
| Total assets | $23.21M | $19.49M | $13.24M | $23.88M | — | +19.1% |
| Total current liabilities | $19.73M | $16.90M | $15.14M | $10.22M | — | +16.8% |
| Total debt | $8.37K | $105.60K | $197.19K | $283.45K | — | -92.1% |
| Total liabilities | $19.73M | $16.91M | $15.25M | $10.41M | — | +16.7% |
| Retained earnings | -$146.76M | -$102.65M | -$78.15M | -$55.77M | — | -43.0% |
| Shareholder equity | $3.48M | $2.58M | -$2.01M | $13.46M | — | +34.9% |
| Working capital | $3.07M | $2.11M | -$2.62M | $12.93M | — | +45.3% |
| Net tangible assets | $3.07M | $2.11M | -$2.53M | $13.03M | — | +45.3% |
| Shares issued | 79.65M | 70.33M | 59.61M | 58.78M | — | +13.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$44.12M | -$24.25M | -$22.38M | -$20.72M | — | -81.9% |
| Depreciation & amortisation | $55.80K | $83.80K | $145.00K | $115.11K | — | -33.4% |
| Stock-based compensation | $5.39M | $6.04M | $6.04M | $2.77M | — | -10.7% |
| Change in working capital | $657.46K | $838.56K | -$240.35K | $2.11M | — | -21.6% |
| Operating cash flow | -$19.50M | -$16.84M | -$11.30M | -$17.78M | — | -15.8% |
| Capital expenditure | — | — | -$141.40K | -$21.11K | -$45.09K | — |
| Investing cash flow | $100.93K | $58.87K | -$138.85K | -$21.11K | — | +71.4% |
| Financing cash flow | $23.76M | $22.70M | $766.28K | $22.64M | — | +4.7% |
| Free cash flow | -$19.50M | -$16.84M | -$11.44M | -$17.81M | — | -15.8% |
| End cash position | $22.07M | $17.27M | $11.66M | $22.45M | — | +27.8% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $4.86M | $3.60M | $4.44M | $2.71M | $3.15M | +35.0% |
| Selling, general & admin | $2.67M | $2.80M | $1.73M | $3.76M | $2.89M | -4.7% |
| Total operating expense | $7.53M | $6.40M | $6.17M | $6.47M | $6.04M | +17.6% |
| Operating income | -$7.53M | -$6.40M | -$6.17M | -$6.47M | -$6.04M | -17.6% |
| Net interest income | $104.07K | $61.68K | $77.07K | $86.90K | $107.76K | +68.7% |
| Pre-tax income | -$1.68M | -$26.91M | -$4.16M | -$9.10M | -$3.95M | +93.8% |
| Net income | -$1.68M | -$26.91M | -$4.16M | -$9.10M | -$3.95M | +93.8% |
| Net income to common | -$1.68M | -$26.91M | -$4.16M | -$9.10M | -$3.95M | +93.8% |
| Basic EPS | -0.02 | — | -0.06 | -0.13 | -0.06 | — |
| Diluted EPS | -0.09 | — | -0.06 | -0.13 | -0.06 | — |
| EBIT | -$7.53M | -$6.40M | -$6.17M | -$6.47M | -$6.04M | -17.6% |
| EBITDA | -$7.53M | -$6.39M | -$6.16M | -$6.46M | -$6.02M | -17.9% |
| Basic shares | 79.90M | — | 73.16M | 71.96M | 70.67M | — |
| Diluted shares | 80.86M | — | 73.16M | 71.96M | 70.67M | — |
| Line item | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $22.07M | $11.36M | $15.67M | $14.47M | $17.27M | +94.2% |
| Cash & short-term investments | $22.08M | $11.40M | $15.73M | $14.55M | $17.36M | +93.7% |
| Total current assets | $22.80M | $12.65M | $16.49M | $15.39M | $19.01M | +80.2% |
| Property, plant & equipment | $0 | — | — | — | $0 | — |
| Goodwill & intangibles | $409.16K | $423.11K | $437.06K | $451.01K | $464.96K | -3.3% |
| Total assets | $23.21M | $13.08M | $16.92M | $15.84M | $19.49M | +77.5% |
| Total current liabilities | $19.73M | $16.02M | $17.84M | $14.45M | $16.90M | +23.2% |
| Total debt | $8.37K | $33.23K | $57.71K | $81.84K | $105.60K | -74.8% |
| Total liabilities | $19.73M | $16.02M | $17.84M | $14.45M | $16.91M | +23.2% |
| Retained earnings | -$146.76M | -$119.85M | -$115.21M | -$106.11M | -$102.65M | -22.5% |
| Shareholder equity | $3.48M | -$2.94M | -$918.42K | $1.39M | $2.58M | +218.2% |
| Working capital | $3.07M | -$3.36M | -$1.36M | $938.47K | $2.11M | +191.2% |
| Net tangible assets | $3.07M | -$3.36M | -$1.36M | $938.47K | $2.11M | +191.2% |
| Shares issued | 79.65M | 73.41M | 72.84M | 70.94M | 70.33M | +8.5% |
| Line item | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$26.91M | -$4.16M | -$9.10M | -$3.95M | -$8.61M | -547.5% |
| Depreciation & amortisation | $13.95K | $13.95K | $13.95K | $13.95K | $15.81K | 0.0% |
| Stock-based compensation | $802.53K | $1.11M | $2.02M | $1.46M | $1.67M | -27.9% |
| Change in working capital | -$192.70K | -$298.91K | $793.53K | $355.55K | $743.29K | +35.5% |
| Operating cash flow | -$6.40M | -$5.32M | -$3.67M | -$4.12M | -$3.66M | -20.3% |
| Investing cash flow | $25.23K | $25.23K | $25.23K | $25.23K | $25.23K | -0.0% |
| Financing cash flow | $16.74M | $995.20K | $4.75M | $1.27M | $310.00K | +1,582.3% |
| Free cash flow | -$6.40M | -$5.32M | -$3.67M | -$4.12M | -$3.66M | -20.3% |
| End cash position | $22.07M | $11.36M | $15.67M | $14.47M | $17.27M | +94.2% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.75
+8.26% from price
SMA 20
1.70
+9.65% from price
SMA 50
1.82
+2.05% from price
SMA 100
2.61
-27.67% from price
SMA 200
3.39
-45.07% from price
EMA 12
1.74
+8.34% from price
EMA 26
1.76
+7.38% from price
EMA 50
1.95
-2.92% from price
RSI (14)
59.4
Neutral
MACD (12,26,9)
-0.02
Hist 0.03
ATR (14)
0.09
4.83% of price
Realised vol 30D
45.6%
Annualised
Bollinger upper
1.83
20, 2σ
Bollinger lower
1.56
20, 2σ
50 / 200 cross
Death
1.82 vs 3.39
Trend bias
Below 200
-45.07%
Risk profile
Beta vs SPY
1.68
More volatile than market
Correlation to SPY
0.25
Largely independent
Realised vol 30D
45.6%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-73.4%
Peak to trough
Max drawdown 5Y
-73.4%
Peak to trough
ATR 14
0.09
4.83% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates
GlobeNewswire · 10d ago
TD Cowen Initiates NervGen Pharma at Buy
MT Newswires · 73d ago
NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study
GlobeNewswire · 89d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.